Core Viewpoint - Citigroup's research report indicates that Giant Bio's revenue grew by 23% in the first half of the year, aligning with expectations, while net profit increased by 20%, exceeding the bank's forecast by 4% [1] Financial Performance - Revenue growth of 23% in the first half of the year meets expectations [1] - Net profit growth of 20% surpasses Citigroup's expectations by 4% [1] Management Outlook - Management anticipates that savings in marketing expenses will provide room for advertising and promotional budgets in the second half of the year [1] - The company maintains its targets for 2025, projecting revenue growth of 25% to 28% and net profit growth of 21% to 24% [1] Analyst Rating and Price Target - Citigroup maintains a "Buy" rating for Giant Bio, raising the target price from HKD 60.7 to HKD 69.4 [1] - Net profit forecasts for 2025 to 2027 have been increased by 5% to 6%, with expected annual growth rates of 20% [1] - Revenue is projected to grow by 26%, 25%, and 23% for the years 2025, 2026, and 2027 respectively [1]
大行评级｜花旗：上调巨子生物目标价至69.4港元 上调2025至27年净利润预测